Doxylamine EP Impurity B

Formulation and evaluation of orodispersible tablet of taste masked doxylamine succinate using ion exchange resin
T.Y.PuttewaraM.D.KshirsagaraA.V.ChandewaraR.V.Chikhale
Journal of King Saud University – Science Volume 22, Issue 4, October 2010, Pages 229-240
 
HPLC-UV method development and impurity profiling of the marine anticancer agent aplidine in raw drug substance and pharmaceutical dosage form
B. Nuijen,1,* I. M. Rodrigues-Campos,2 C. P. Noain,2 P. Floriano,2 C. Manada,2 M. Bouma,1 J. J. Kettenes-van den Bosch,3 A. Bult,4 and J. H. Beijnen
J. liq. chrom. & rel. technol., 24(20), 3119–3139 (2001)
 
Simultaneous determination of clobutinol hydrochloride and doxylamine succinate from syrups by RP HPLC using a new stationary phase containing embedded urea polar groups
Paulo Cesar Pires Rosa1,*, Isabel Cristina Sales Fontes Jardim
Braz. J. Pharm. Sci. vol.48 no.2 São Paulo Apr./June 2012

Doxylamine EP Impurity B is chemically (R)-1-Phenyl-1-(pyridin-2-yl)ethan-1-ol. Doxylamine EP Impurity B is supplied with detailed characterization data compliant with regulatory guideline. Doxylamine EP Impurity B can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Doxylamine.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.